Publications

Journal Article
Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.
Ppublish 66 citations
Electronic publication date
May 19, 2009

View on Pubmed.gov 19002432 | View on doi.org 10.1007/s00125-...

Amyloid formation results in recurrence of hyperglycaemia following transplantation of human IAPP transgenic mouse islets.

Search for publications in this journal Diabetologia - 52(1):145-53

  • J Udayasankar

    Search for this expert
    1
  • K Kodama
  • R L Hull
  • S Zraika
  • K Aston-Mourney

    Search for this expert
  • S L Subramanian

    Search for this expert
  • J Tong

    Search for this expert
  • M V Faulenbach

    Search for this expert
  • J Vidal

    Search for this expert
  • S E Kahn

Abstract

AIMS/HYPOTHESIS

Islet transplantation is a potential cure for diabetes; however, rates of graft failure remain high. The aim of the present study was to determine whether amyloid deposition is associated with reduced beta cell volume in islet grafts and the recurrence of hyperglycaemia following islet transplantation.

METHODS

We transplanted a streptozotocin-induced mouse model of diabetes with 100 islets from human IAPP (which encodes islet amyloid polypeptide) transgenic mice that have the propensity to form islet amyloid (n = 8-12) or from non-transgenic mice that do not develop amyloid (n = 6-10) in sets of studies that lasted 1 or 6 weeks.

RESULTS

Plasma glucose levels before and for 1 week after transplantation were similar in mice that received transgenic or non-transgenic islets, and at that time amyloid was detected in all transgenic grafts and, as expected, in none of the non-transgenic grafts. However, over the 6 weeks following transplantation, plasma glucose levels increased in transgenic but remained stable in non-transgenic islet graft recipients (p < 0.05). At 6 weeks, amyloid was present in 92% of the transgenic grafts and in none of the non-transgenic grafts. Beta cell volume was reduced by 30% (p < 0.05), beta cell apoptosis was twofold higher (p < 0.05), and beta cell replication was reduced by 50% (p < 0.001) in transgenic vs non-transgenic grafts. In summary, amyloid deposition in islet grafts occurs prior to the recurrence of hyperglycaemia and its accumulation over time is associated with beta cell loss.

CONCLUSIONS/INTERPRETATION

Islet amyloid formation may explain, in part, the non-immune loss of beta cells and recurrence of hyperglycaemia following clinical islet transplantation.

References

Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3492-6

Transplantation. 2003 Jul 15;76(1):92-8

N Engl J Med. 2008 Aug 28;359(9):977-9

Nature. 1994 Apr 21;368(6473):756-60

Cited by 66 citations (total)

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes.

Electronic publication date November 4, 2010

Search for publications in this journal Nat Immunol

Seth L Masters [...] Luke A J O'Neill et al.

Interleukin 1β (IL-1β) is an important inflammatory mediator of type 2 diabetes. Here we show that oligomers of islet amyloid...

Journal Article Research Support, N.I.H., Extramural Review

Mechanisms of islet amyloidosis toxicity in type 2 diabetes.

Electronic publication date June 1, 2013

Search for publications in this journal FEBS Lett

Andisheh Abedini [...] Ann Marie Schmidt et al.

Amyloid formation by the neuropancreatic hormone, islet amyloid polypeptide (IAPP or amylin), one of the most amyloidogenic sequences known, leads...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances